Información del artículo
El Texto completo está disponible en PDF
References
[1.]
I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, et al.
Gastroenteropancreatic neuroendocrine tumors.
Lancet Oncol, 9 (2008), pp. 61-72
[2.]
D.J. Fox, R.S. Khattar.
Carcinoid heart disease: presentation, diagnosis and management.
Heart, 90 (2004), pp. 1224-1228
[3.]
A.M. Bernheim, H.M. Connolly, P.A. Pellikka.
Carcinoid heart disease.
Curr Treat Options Cardiovasc Med, 9 (2007), pp. 482-489
[4.]
I. Cruz-González, J. Solis, I. Inglessis-Azuaje, I.F. Palacios.
Foramen oval permeable: situación actual.
Rev Esp Cardiol, 61 (2008), pp. 738-751
[5.]
K.A. Mizuguchi, A.A. Fox, T.M. Burch, L.H. Cohn, J.A. Fox.
Tricuspid and mitral valve carcinoid disease in the setting of a patent foramen ovale.
Anesth Analg, 107 (2008), pp. 1819-1821
[6.]
U. Plöckinger, B. Gustafsson, D. Ivan, W. Szpak, J. Daver.
ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: echocardiography.
Neuroendocrinology, 90 (2009), pp. 190-193
[7.]
H. Van, P. Poommipanit, M. Shalaby, R. Gevorgyan, C.H. Tseng, J. Tobis.
Sensitivity of transcranial Doppler versus intracardiac echocardiography in the detection of right-to-left shunt.
JACC Cardiovasc Imaging, 3 (2010), pp. 343-348
[8.]
P.M. Motram, D.J. McGraw, I.T. Meredith, R.E. Peverill, R.W. Harper.
Profound hypoxaemia corrected by PFO closure device in carcinoid heart disease.
Eur J Echocardiog, 9 (2008), pp. 47-49
[9.]
N. Masencal, I. Touhami, E. Mitry, P. Rougier, O. Ducourg.
Patent foramen ovale in carcinoid heart disease.
Int J Cardiol, 9 (2010),
[10.]
M. Appetecchia, R. Baldelli.
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours;current aspects and new perspectives.
J Exp Clin Cancer Res, 29 (2010),
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
